Calcipotriol cream: A review of its use in the management of psoriasis

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 327-337

  Segaert, Siegfried ^a   Duvold, Laëtitia Bouérat ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LEO PHARMA A S   (Denmark)

Author keywords

Calcipotriol; Cream; Psoriasis; Topical treatment; Vitamin D

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASONE BUTYRATE; COAL TAR;

APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN ATROPHY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CALCITRIOL; DERMATOLOGIC AGENTS; DOSAGE FORMS; HUMANS; PSORIASIS;

EID: 34250184638     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600999219     Document Type: Review

References (41)

1. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912.
2. Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol. 2004;5:463-78.
3. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416-30.
4. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: A systematic review. Br J Dermatol. 2002;146:351-64.
5. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol. 1992;127:266-71.
6. Pinheiro N. Comparative effects of calcipotriol ointment (50 μg/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract. 1997;51:16-19.
7. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol. 1997;137:581-6.
8. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2:95-120.
9. Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Investig Drugs. 1998;7:77-84.
10. Arnold WP, van de Kerkhof PC. The induction of epidermal ornithine decarboxylase following tape stripping is inhibited by a topical vitamin D3 analogue (MC903). Br J Dermatol. 1991;125:6-8.
11. Glade CP, Van Erp PE, Van De Kerkhof PC. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: A comparative flow cytometric study. Br J Dermatol. 1996;135:379-84.
12. Dam TN, Moller B, Hindkjaer J, Kragballe K. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Investig Dermatol Symp Proc. 1996;1:72-7.
13. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
14. Harrington CI, Goldin D, Lovell CR, van de Kerkhof P, Nieboer C, Austad J, et al. Comparative effects of two different calcipotriol (MC903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol. 1996;6:152-8.
15. Ferrandiz C, Bielsa I, Ribera M, Fuente MJ, Carrascosa JM. Reinforcement therapy in patients with psoriasis treated with calcipotriol cream. Actas Dermosifiliogr. 1998;89:626-30.
16. Stadler R, Bohmeyer J. [Regarding the effectiveness and tolerability of a cream containing calcipotriol (Psorcutan®) in the treatment of psoriasis vulgaris.] Z Hautkr. 1998;73:593-6.
17. Duweb G, Aldebani S, Elzorghany A, Benghazil M, Alhaddar J. Calcipotriol ointment versus cream in psoriasis vulgaris. Int J Clin Pharmacol Res. 2003;23:47-51.
18. Van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2003;16:69-83.
19. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: Tolerability and efficacy. Br J Dermatol. 1998;139:649-54.
20. Stücker M, Memmel U, Hoffmann M, Hartung J, Altmeyer P. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology. 2001;203:141-7.
21. Molin L, Cutler TP, Helander I, Nyfors B, Downes N. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Br J Dermatol. 1997;136:89-93.
22. Tzaneva S, Hönigsmann H, Tanew A. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex®) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol. 2003;149:350-3.
23. White S, Vender R, Thaci D, Swinkels Q, Naeyaert JM, Foster R, et al. Use of calcipotriene cream (Dovonex® cream) following acute treatment of psoriasis vulgaris with calcipotriene/betamethasone dipropionate two-compound product (Taclonex®): A randomised, parallel group clinical trial. Am J Clin Dermatol. 2006;7:177-84.
24. Cassano N, Miracapillo A, Coviello C, Lo console F, Bellino M, Vena GA. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Invest. 2006;26:227-33.
25. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol. 2000;10:199-204.
26. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PC, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology. 1994;189:260-4.
27. Meyrat R, Mueller I. Daivonex® ointment daily versus Daivonex® cream in the morning and Daivonex® ointment in the evening. Ars Med. 1996;86:1218-20.
28. Van de Kerkhof PC, Franssen M, de la Brassine M, Kuipers M. Calcipotriol cream in the morning and ointment in the evening: A novel regimen to improve compliance. J Dermatolog Treat. 2001;12:75-9.
29. Vena GA, Cassano N, Agnusdei CP, Bellini M, Calabretta S, Centofanti S, et al. Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflamm. 2005;3:37-42.
30. Schlehaider UK, Kowalzick L. Cream based calcipotriol for the treatment of 'inverse' psoriasis and seborrheic dermatitis. Aktuelle Derm. 1996;22:345-8.
31. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex®) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135:390-3.
32. Pauluzzi P, Doria A, Nobile C, Trevisan G. Calcipotriol cream in childhood psoriasis. Acta Dermatovenerol Alp Panonica Adriat. 1999;8:119-21.
33. Duweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React. 2003;25:127-30.
34. Halbaut L, Alcalde MT, Aróztegui M, Barbé C. [Relation between the physicochemical characteristics and the sensorial properties of topical pharmaceutical products. II Sensorial analysis. ] Cienc Pharm. 1996;6:289-96.
35. Halbaut L, Alcalde MT, Aróztegui M, Barbé C. [Sensory analysis and rheological properties: determining factors.]. In: 1st Mediterranean Congress of Cosmetology: Efficacy and Innocuity: New trends in relation with the European dossier. France: La Grande Motte; 1996. p. 260-80.
36. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-98.
37. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
38. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-5.
39. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet®) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-93.
40. Guenther L, van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316-23.
41. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-73.